Leerink Partnrs Forecasts Penumbra's Q3 Earnings (NYSE:PEN)

Penumbra, Inc. (NYSE:PEN - Free Report) - Equities researchers at Leerink Partnrs lifted their Q3 2025 earnings per share estimates for shares of Penumbra in a report issued on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $1.00 per share for the quarter, up from their prior estimate of $0.98. The consensus estimate for Penumbra's current full-year earnings is $3.67 per share. Leerink Partnrs also issued estimates for Penumbra's Q4 2025 earnings at $1.15 EPS and FY2025 earnings at $3.81 EPS.

Penumbra (NYSE:PEN - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 EPS for the quarter, beating analysts' consensus estimates of $0.66 by $0.17. Penumbra had a net margin of 1.17% and a return on equity of 9.74%. The company had revenue of $324.14 million during the quarter, compared to analyst estimates of $315.72 million. During the same period last year, the business earned $0.41 earnings per share. Penumbra's revenue was up 16.3% compared to the same quarter last year.

Other equities analysts have also recently issued reports about the company. Royal Bank of Canada boosted their target price on Penumbra from $315.00 to $330.00 and gave the stock an "outperform" rating in a research report on Thursday, April 24th. Morgan Stanley boosted their price objective on Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 19th. Canaccord Genuity Group raised their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a research note on Wednesday, February 19th. Truist Financial boosted their price target on shares of Penumbra from $315.00 to $330.00 and gave the stock a "buy" rating in a research note on Thursday, April 24th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Penumbra Price Performance

Shares of Penumbra stock traded up $2.05 during trading on Monday, hitting $293.87. The stock had a trading volume of 81,813 shares, compared to its average volume of 425,762. The company has a current ratio of 6.01, a quick ratio of 3.25 and a debt-to-equity ratio of 0.02. Penumbra has a 12 month low of $148.00 and a 12 month high of $310.00. The firm has a market cap of $11.38 billion, a price-to-earnings ratio of 864.31, a P/E/G ratio of 2.83 and a beta of 0.56. The business's 50-day moving average is $276.82 and its 200 day moving average is $256.96.

Insider Buying and Selling

In related news, EVP Johanna Roberts sold 600 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $287.43, for a total value of $172,458.00. Following the completion of the sale, the executive vice president now owns 66,539 shares of the company's stock, valued at $19,125,304.77. This trade represents a 0.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Thomas Wilder sold 360 shares of the business's stock in a transaction on Monday, March 31st. The shares were sold at an average price of $264.58, for a total transaction of $95,248.80. Following the transaction, the director now directly owns 4,533 shares in the company, valued at approximately $1,199,341.14. The trade was a 7.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 140,446 shares of company stock valued at $39,543,953 over the last three months. 5.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Penumbra

A number of large investors have recently modified their holdings of the stock. Louisiana State Employees Retirement System lifted its holdings in Penumbra by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 10,800 shares of the company's stock worth $2,888,000 after buying an additional 100 shares during the period. New York State Common Retirement Fund raised its position in shares of Penumbra by 18.2% in the 1st quarter. New York State Common Retirement Fund now owns 72,333 shares of the company's stock worth $19,343,000 after acquiring an additional 11,143 shares in the last quarter. Rational Advisors Inc. bought a new position in Penumbra in the first quarter worth $3,262,000. Diversify Wealth Management LLC lifted its position in Penumbra by 50.0% during the first quarter. Diversify Wealth Management LLC now owns 2,467 shares of the company's stock valued at $733,000 after buying an additional 822 shares during the period. Finally, State of Michigan Retirement System grew its position in shares of Penumbra by 1.1% in the 1st quarter. State of Michigan Retirement System now owns 9,214 shares of the company's stock worth $2,464,000 after buying an additional 100 shares during the period. Institutional investors own 88.88% of the company's stock.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.